Lucid Diagnostics to Engage at the Maxim Growth Summit 2025 in New York

Lucid Diagnostics Set to Shine at 2025 Maxim Growth Summit

Lucid Diagnostics Inc. (Nasdaq: LUCD), a pioneering company in cancer prevention medical diagnostics, has announced its participation in the 2025 Maxim Growth Summit. This event will take place from October 22 to 23, 2025, in New York City, a hub for innovation and investment.

About Lucid Diagnostics

As a subsidiary of PAVmed Inc. (Nasdaq: PAVM), Lucid is on a mission—to mitigate cancer risk and enhance early detection methods for patients suffering from gastroesophageal reflux disease (GERD), also known as chronic heartburn. This condition puts millions at risk of developing serious health issues like esophageal precancer and cancer.

Lucid's flagship product, the EsoGuard® Esophageal DNA Test, enables healthcare providers to identify at-risk patients through a simple, non-invasive office procedure using the EsoCheck® Esophageal Cell Collection Device. This test stands out as a unique, commercially available solution aiming to prevent cancer deaths through early detection.

Engagement Plans at the Summit

During the upcoming summit, Lucid’s Chief Financial Officer, Dennis McGrath, will spearhead multiple one-on-one meetings with investors. This is a notable opportunity for stakeholders to engage directly with Lucid's leadership and discuss the company's strategic direction and innovations in cancer diagnostics. Interested investors are encouraged to reach out to their Maxim representative to schedule a meeting.

The Maxim Growth Summit itself is renowned for bringing together a diverse group of investors and thought leaders from various sectors, focusing on promising companies poised for growth. Participating in this summit positions Lucid Diagnostics not only to showcase its groundbreaking technologies but also to strengthen relationships within the investment community.

Future Aspirations

Lucid Diagnostics is determined to remain at the forefront of cancer prevention and early detection. Their commitment aligns with ongoing industry trends that favor preventative healthcare and innovative diagnostic solutions. The company is keenly aware of the challenges in research and development and acknowledges the uncertainties involved in the regulatory approval process for its products.

The healthcare landscape is evolving, and Lucid is strategically positioned to capitalize on its unique offerings while responding to the needs of both healthcare providers and patients.

In light of the global health challenges posed by the COVID-19 pandemic, Lucid remains flexible and is continuously adapting its strategies to meet changing market demands. As they prepare for the summit and beyond, Lucid Diagnostics is focused on bringing transformative solutions to patients worldwide.

For those keen on learning more about Lucid Diagnostics and their innovative cancer screening products, additional information can be found on their official website at www.luciddx.com. Furthermore, insights into their parent company PAVmed Inc. can be accessed at www.pavmed.com.

As Lucid Diagnostics gears up for the 2025 Maxim Growth Summit, it underscores the vital role of accessible and effective cancer screening in significantly improving patient outcomes and reducing the future incidence of cancer.